Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

The 2022 Tandem Meetings | Belimumab for the prophylaxis of chronic GvHD

John DiPersio • 23 Apr 2022

The 2022 Tandem Meetings

General Antibodies Belimumab

John DiPersio, MD, PhD, Washington University, St. Louis, MO, discusses the rationale for using belimumab for the prophylaxis of chronic graft-versus-host disease (cGvHD). By binding to the B-cell activating factor released by alloreactive T-cells, belimumab also blocks the activation of B-cells, which play an important role in cGvHD and cGvHD-related complications. A recent study showed that patients treated with belimumab have significantly lower rates of cGvHD and experienced no important side effects. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Identifying the optimal toxic payloads for antibody-based SCT conditioning using SAv-drug conjugates

John DiPersio • 21 Feb 2023

LBA: CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT

John DiPersio • 21 Feb 2023

ALL highlights: tisa-cel reinfusion in B-ALL & targeting CD5 and CD7 with CAR-Ts in T-ALL

John DiPersio • 21 Feb 2023

Advantages & concerns associated with the use of ADC-based conditioning in SCT recipients

John DiPersio • 21 Feb 2023

Related Videos

The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024

Natacha Bolaños • 16 Apr 2024

Distinguishing late-onset neutropenia from classical primary neutropenia

Carlo Dufour • 15 Apr 2024

The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract

James Ferrara • 16 Apr 2024

The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives

Claire Horgan • 15 Apr 2024